FDA OKs Flu Vaccines for 2008-09 Season Aug 7, 2008
The six vaccines for the 2008-09 season and their manufacturers are: CSL Limited, Afluria; GlaxoSmithKline Biologicals, Fluarix; ID Biomedical Corporation of Quebec, FluLaval; MedImmune Vaccines Inc., FluMist; Novartis Vaccines and Diagnostics Limited, Fluvirin; and Sanofi Pasteur Inc., Fluzone. They are designed to protect against A/Brisbane/59/2007 (H1N1)-like virus; an A/Brisbane/10/2007 (H3N2)-like virus; and a B/Florida/4/2006-like virus, the FDA said on its Web site. (MEDLINEplus)
FDA Approves FluLaval(TM) (Influenza Virus Vaccine) Oct 8, 2006
GSK added FluLaval to its portfolio of flu products when it acquired the Canadian vaccine manufacturer ID Biomedical Corporation in December 2005. FluLaval, which will be available in 10 dose multi-dose vials, was granted fast track review status by the FDA in July 2005. (DG News)
FDA Approves Additional Vaccine for Upcoming Influenza Season Oct 6, 2006
FluLaval is manufactured by ID Biomedical Corporation of Quebec, Canada, a subsidiary of GlaxoSmithKline Biologics and will be distributed by GlaxoSmithKline, Research Triangle Park, N.C.. FluLaval is the second seasonal influenza vaccine approved using the accelerated approval process; GlaxoSmithKline's Fluarix received approval in 2005. (FDA.gov)
Response Biomedical Closes $12 Million Financing Mar 31, 2006
With the closing of the financing, Response Biomedical also announced the appointment of five former Directors and Senior Executives of ID Biomedical Corporation to Response Biomedical's Board of Directors. Effective immediately, Dr. Anthony Holler, Mr. Todd Patrick, Dr. Richard Bastiani, Mr. Richard Bear and Mr. Ian Webb, former Chief Executive Officer, President and Chief Operating Officer, Chairman of the Board, Chief Financial Officer, and Director, respectively, of ID Biomedical Corporation... (PR Newswire)
Glaxo starts bird flu vaccine trials Mar 31, 2006
Glaxo also bought a Canadian influenza vaccine manufacturer, ID Biomedical Corporation. "The production capacity of the newly acquired Canadian facilities -- combined with GSK's expanded vaccines manufacturing plant in Dresden, Germany -- is expected to reach around 150 million doses per year by 2008," Glaxo said in a statement. (Reuters AlertNet)
GlaxoSmithKline Initiates Human Trial Program With Two H5N1 Pandemic Flu Vaccines Mar 30, 2006
In North America, GSK recently acquired a major influenza vaccine manufacturer, ID Biomedical Corporation. This acquisition provides GSK with a significant increase in flu vaccine manufacturing capacity. (PR Newswire)
